Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Published on 04 Jan 2022
Last Updated on 04 Jan 2022

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:

  • neovascular (wet) age-related macular degeneration;

  • diabetic macular oedema; and

  • macular oedema secondary to central or branch retinal vein occlusion

in view of an acceptable price proposal from the manufacturer.

Subsidy status

Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion (4 Jan 2022) [PDF, 124 KB]